BR112019000897A2 - sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão. - Google Patents
sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão.Info
- Publication number
- BR112019000897A2 BR112019000897A2 BR112019000897-7A BR112019000897A BR112019000897A2 BR 112019000897 A2 BR112019000897 A2 BR 112019000897A2 BR 112019000897 A BR112019000897 A BR 112019000897A BR 112019000897 A2 BR112019000897 A2 BR 112019000897A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- acid addition
- addition salt
- attenuating
- tissue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Secondary Cells (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
são providos sais de derivados de 2,6-dimetilpirimidona e usos dos mesmos. são providas também composições farmacêuticas contendo os sais.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610598745.1 | 2016-07-27 | ||
CN201610598745 | 2016-07-27 | ||
PCT/CN2017/093521 WO2018019166A1 (en) | 2016-07-27 | 2017-07-19 | Salts of 2, 6-dimethylpyrimidone derivatives and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019000897A2 true BR112019000897A2 (pt) | 2019-04-30 |
Family
ID=61015603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019000897-7A BR112019000897A2 (pt) | 2016-07-27 | 2017-07-19 | sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão. |
Country Status (12)
Country | Link |
---|---|
US (1) | US10647682B2 (pt) |
EP (1) | EP3490978B1 (pt) |
JP (1) | JP7030779B2 (pt) |
KR (1) | KR102455383B1 (pt) |
CN (1) | CN107663177B (pt) |
AR (1) | AR109168A1 (pt) |
AU (1) | AU2017304779B2 (pt) |
BR (1) | BR112019000897A2 (pt) |
CA (1) | CA3031343A1 (pt) |
ES (1) | ES2963851T3 (pt) |
TW (1) | TW201803853A (pt) |
WO (1) | WO2018019166A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10851068B2 (en) | 2017-07-14 | 2020-12-01 | Sunshine Lake Pharma Co., Ltd. | Method for preparing pyrimidone compound |
CN112770757B (zh) * | 2018-10-19 | 2024-01-16 | 广东东阳光药业股份有限公司 | 一种治疗纤维化疾病的药物组合或药物组合物 |
CN112851640B (zh) * | 2019-11-28 | 2023-09-01 | 广东东阳光药业股份有限公司 | 嘧啶苯甲酰胺化合物的硫酸盐及其用途 |
TW202320764A (zh) * | 2021-08-27 | 2023-06-01 | 日商科研製藥股份有限公司 | 2-(4-乙基苯氧基)-4’-甲氧基-3,3’-聯吡啶的結晶及其製造方法 |
CN115957221A (zh) | 2021-10-09 | 2023-04-14 | 广东东阳光药业有限公司 | 抗纤维化组合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101235013A (zh) * | 2008-03-10 | 2008-08-06 | 广东东阳光药业有限公司 | 结晶型1-(3-氟苯基)-5-甲基-2-(1h)吡啶酮、其制备方法、及其组合物和应用 |
JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン, インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
US9434695B2 (en) * | 2012-07-18 | 2016-09-06 | Sunshine Lake Pharma Co., Ltd | Nitrogenous heterocyclic derivatives and their application in drugs |
-
2017
- 2017-07-19 EP EP17833469.4A patent/EP3490978B1/en active Active
- 2017-07-19 WO PCT/CN2017/093521 patent/WO2018019166A1/en unknown
- 2017-07-19 KR KR1020197005477A patent/KR102455383B1/ko active IP Right Grant
- 2017-07-19 JP JP2019503651A patent/JP7030779B2/ja active Active
- 2017-07-19 CN CN201710591845.6A patent/CN107663177B/zh active Active
- 2017-07-19 BR BR112019000897-7A patent/BR112019000897A2/pt not_active IP Right Cessation
- 2017-07-19 AU AU2017304779A patent/AU2017304779B2/en active Active
- 2017-07-19 CA CA3031343A patent/CA3031343A1/en active Pending
- 2017-07-19 US US16/316,055 patent/US10647682B2/en active Active
- 2017-07-19 ES ES17833469T patent/ES2963851T3/es active Active
- 2017-07-24 TW TW106124794A patent/TW201803853A/zh unknown
- 2017-07-26 AR ARP170102111A patent/AR109168A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2019522015A (ja) | 2019-08-08 |
TW201803853A (zh) | 2018-02-01 |
US20190308939A1 (en) | 2019-10-10 |
KR102455383B1 (ko) | 2022-10-18 |
ES2963851T3 (es) | 2024-04-02 |
WO2018019166A1 (en) | 2018-02-01 |
AR109168A1 (es) | 2018-11-07 |
EP3490978A1 (en) | 2019-06-05 |
EP3490978A4 (en) | 2020-08-26 |
KR20190034586A (ko) | 2019-04-02 |
US10647682B2 (en) | 2020-05-12 |
JP7030779B2 (ja) | 2022-03-07 |
CN107663177B (zh) | 2022-07-08 |
CA3031343A1 (en) | 2018-02-01 |
AU2017304779B2 (en) | 2020-12-17 |
CN107663177A (zh) | 2018-02-06 |
AU2017304779A1 (en) | 2019-02-14 |
EP3490978B1 (en) | 2023-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019000897A2 (pt) | sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão. | |
BR112019003504A2 (pt) | compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos | |
BR112019006712A2 (pt) | composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo. | |
BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
BR112021007222A8 (pt) | Moduladores de receptor de androgênio e métodos para seu uso | |
BR112020025274A8 (pt) | Compostos antagonistas de pcsk9 | |
BR112018070549A2 (pt) | degradantes de proteína mdm2 | |
BR112018012756A2 (pt) | compostos heterocíclicos como imunomoduladores | |
BR112018068565A2 (pt) | combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos | |
BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
CR20210281A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr | |
BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
BR112018012408A2 (pt) | ?composto, composição, e, método para tratar um distúrbio de dor ou distúrbio de tosse ou de coceira aguda ou de coceira crônica? | |
BR112016028814A2 (pt) | ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo? | |
BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112017004589A2 (pt) | composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd | |
BR112019000453A2 (pt) | combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas | |
BR112017007239A2 (pt) | inibidor da aurora a cinase, seus usos, e composição farmacêutica". | |
BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
AR101806A1 (es) | Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |